PL398596A1 - Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α - Google Patents

Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α

Info

Publication number
PL398596A1
PL398596A1 PL398596A PL39859603A PL398596A1 PL 398596 A1 PL398596 A1 PL 398596A1 PL 398596 A PL398596 A PL 398596A PL 39859603 A PL39859603 A PL 39859603A PL 398596 A1 PL398596 A1 PL 398596A1
Authority
PL
Poland
Prior art keywords
tnf
treatment
human antibodies
disorders associated
preparation containing
Prior art date
Application number
PL398596A
Other languages
English (en)
Other versions
PL218221B1 (pl
Inventor
Hans-Juergen Krause
Lisa Baust
Michael Dickes
Original Assignee
Abbott Biotechnology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31714885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL398596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Biotechnology Ltd. filed Critical Abbott Biotechnology Ltd.
Publication of PL398596A1 publication Critical patent/PL398596A1/pl
Publication of PL218221B1 publication Critical patent/PL218221B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
PL398596A 2002-08-16 2003-08-15 Trwały ciekły wodny preparat farmaceutyczny zawierający ludzkie przeciwciała przeciw czynnikowi martwicy nowotworów alfa PL218221B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/222,140 US20040033228A1 (en) 2002-08-16 2002-08-16 Formulation of human antibodies for treating TNF-alpha associated disorders

Publications (2)

Publication Number Publication Date
PL398596A1 true PL398596A1 (pl) 2012-06-18
PL218221B1 PL218221B1 (pl) 2014-10-31

Family

ID=31714885

Family Applications (3)

Application Number Title Priority Date Filing Date
PL398596A PL218221B1 (pl) 2002-08-16 2003-08-15 Trwały ciekły wodny preparat farmaceutyczny zawierający ludzkie przeciwciała przeciw czynnikowi martwicy nowotworów alfa
PL375272A PL212934B1 (pl) 2002-08-16 2003-08-15 Ciekly wodny preparat farmaceutyczny
PL406852A PL218834B1 (pl) 2002-08-16 2003-08-15 Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL375272A PL212934B1 (pl) 2002-08-16 2003-08-15 Ciekly wodny preparat farmaceutyczny
PL406852A PL218834B1 (pl) 2002-08-16 2003-08-15 Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α

Country Status (26)

Country Link
US (27) US20040033228A1 (pl)
EP (5) EP2363145A1 (pl)
JP (5) JP4925582B2 (pl)
KR (4) KR20050067140A (pl)
CN (4) CN101721702B (pl)
AR (2) AR040881A1 (pl)
AT (1) ATE555809T1 (pl)
AU (1) AU2003267744C1 (pl)
BR (1) BR0313492A (pl)
CA (9) CA2494756C (pl)
CL (1) CL2010000603A1 (pl)
CY (2) CY1113353T1 (pl)
DK (2) DK1528933T3 (pl)
ES (2) ES2636692T3 (pl)
IL (2) IL166809A (pl)
MX (1) MXPA05001841A (pl)
MY (3) MY163027A (pl)
NZ (1) NZ538030A (pl)
PE (1) PE20040994A1 (pl)
PL (3) PL218221B1 (pl)
PT (2) PT1528933E (pl)
SI (2) SI1528933T1 (pl)
TW (1) TWI331532B (pl)
UY (1) UY27940A1 (pl)
WO (1) WO2004016286A2 (pl)
ZA (1) ZA200501032B (pl)

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000003I2 (de) * 1996-02-09 2007-03-29 Abbott Biotech Ltd Humane Antikörper welche an humanen TNFalpha Binden
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
CA2800126A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP3417875B1 (en) * 2003-02-10 2020-06-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
JPWO2005063291A1 (ja) * 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
TW200722518A (en) 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
WO2006125229A2 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
US8858935B2 (en) * 2005-05-19 2014-10-14 Amgen Inc. Compositions and methods for increasing the stability of antibodies
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
EP3673919A1 (en) * 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
WO2006138315A2 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-igf1r antibody formulations
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7919264B2 (en) * 2005-11-01 2011-04-05 Abbott Biotechnology Ltd. Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers
EP1798504A1 (en) * 2005-12-19 2007-06-20 Koninklijke Philips Electronics N.V. Method of making dried particles
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
KR20140071452A (ko) * 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
EP2666479A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of juvenile rheumatoid arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) * 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
CN107243099A (zh) 2006-06-30 2017-10-13 艾伯维生物技术有限公司 自动注射装置
PE20081179A1 (es) * 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
WO2008051363A2 (en) * 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
CN104072612A (zh) 2006-10-27 2014-10-01 艾伯维生物技术有限公司 结晶型抗-hTNFα抗体
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
AR066016A1 (es) * 2007-04-11 2009-07-15 Alcon Res Ltd Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
EP2679995A1 (en) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CN101848733A (zh) * 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
CA2697163A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
EP3189831A1 (en) * 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2703997C (en) 2007-12-26 2017-04-04 Xencor, Inc. Fc variants with altered binding to fcrn
EP2240156A2 (en) * 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
CA2710779C (en) 2007-12-31 2017-06-20 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf.alpha.
CA2710333A1 (en) * 2008-01-03 2009-07-09 Abbott Biotechnology Ltd. Predicting long-term efficacy of a compound in the treatment of psoriasis
AU2009204863B2 (en) 2008-01-15 2015-07-16 AbbVie Deutschland GmbH & Co. KG Powdered protein compositions and methods of making same
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
CN102301235B (zh) * 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
KR20120091037A (ko) * 2009-10-01 2012-08-17 알콘 리서치, 리미티드 올로파타딘 조성물 및 그의 용도
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012007042A (es) * 2009-12-15 2012-11-06 Abbott Biotech Ltd Boton de disparo mejorado para dispositivo de inyeccion automatico.
JP2013514388A (ja) 2009-12-16 2013-04-25 フィリップ ボッシュ， 間質性膀胱炎の処置の方法
FR2958646B1 (fr) * 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
AU2011219715B2 (en) 2010-02-26 2014-12-11 Novo Nordisk A/S Stable antibody containing compositions
SG10201903166PA (en) 2010-03-01 2019-05-30 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CA2788060C (en) 2010-03-17 2017-07-11 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
CN103118737B (zh) 2010-04-21 2015-05-20 艾伯维生物技术有限公司 用于治疗药剂的受控输送的可佩戴自动注射装置
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
ES2685607T3 (es) 2010-06-03 2018-10-10 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS)
RU2013109275A (ru) 2010-08-03 2014-09-10 Эббви Инк. Иммуноглобулины с двумя вариабельными доменами и их применение
MX2013002270A (es) 2010-08-26 2013-05-14 Abbvie Inc Inmonoglubinas de dominio variable doble y usos de las mismas.
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
CA2825316C (en) 2011-01-24 2020-05-05 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
PL2668212T3 (pl) 2011-01-28 2018-08-31 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
US9125893B2 (en) 2011-02-17 2015-09-08 Kyowa Hakko Kirin Co., Ltd. Highly concentrated anti-CD40 antibody pharmaceutical preparation
PL3235508T3 (pl) 2011-03-16 2021-07-12 Sanofi Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2704751B1 (en) 2011-05-02 2019-04-17 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
TWI832619B (zh) 2011-05-02 2024-02-11 美商千禧製藥公司 抗-α４β７抗體之調配物
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
SG11201401360XA (en) 2011-10-25 2014-05-29 Onclave Therapeutics Ltd Antibody formulations and methods
MX2014008101A (es) 2011-12-30 2014-09-25 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
US9757460B2 (en) 2012-01-23 2017-09-12 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
EP3912639A1 (en) * 2012-03-07 2021-11-24 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
US9592289B2 (en) * 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
HK1204990A1 (en) * 2012-03-26 2015-12-11 Sanofi Stable igg4 binding agent formulations
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20150150982A1 (en) * 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
PT3181119T (pt) 2012-09-12 2019-10-18 Novaliq Gmbh Composições de alcano semiflourado para utilização no tratamento de queratoconjuntivite seca
RU2664691C2 (ru) * 2012-10-26 2018-08-21 Люпин Лимитед Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
EP2934587A4 (en) * 2012-12-18 2016-08-03 Merck Sharp & Dohme Liquid formulations for an anti-TNF-alpha-antibody
CN102988984B (zh) * 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
KR20150110659A (ko) * 2013-01-24 2015-10-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tnf-알파 항원-결합 단백질
EP3656786B1 (en) 2013-02-08 2024-08-28 Novartis AG Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
SG11201507365VA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
CA2899308C (en) 2013-03-14 2017-04-18 Abbvie Inc. Low acidic species adalimumab compositions and uses thereof
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
CN105143257B (zh) 2013-03-15 2020-10-27 艾伯维生物医疗股份有限公司 Fc变体
CN103446583B (zh) * 2013-03-21 2015-11-18 百奥泰生物科技(广州)有限公司 一种治疗TNF-α相关疾病的人抗体制剂
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
EP3003369A4 (en) * 2013-05-28 2017-04-26 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions comprising pyrophosphate
HK1214531A1 (zh) * 2013-06-24 2016-07-29 豪夫迈．罗氏有限公司 稳定的静脉内制剂
US20160151484A1 (en) 2013-07-19 2016-06-02 Hexal Ag Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
MX370207B (es) * 2013-07-23 2019-12-05 Novaliq Gmbh Composiciones estabilizadas de anticuerpos.
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
MX374124B (es) 2013-10-16 2025-03-05 Outlook Therapeutics Inc Formulaciones de tampón para la estabilidad de anticuerpo mejorada.
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
SI2838510T1 (sl) * 2013-11-08 2016-11-30 Eli Lilly And Company Lilly Corporate Center Raztopina atomoksetina
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
ES2983564T3 (es) 2013-11-21 2024-10-23 Genmab As Formulación liofilizada de conjugado de anticuerpos y fármaco
CN104666242B (zh) * 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 一种稳定的抗TNF‑α抗体制剂及其用途
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP2960252A1 (en) * 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
WO2015151115A1 (en) 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
CN105012949A (zh) * 2014-04-28 2015-11-04 上海药明康德新药开发有限公司 重组人抗人TNFα单克隆抗体的制剂
EP2946767B1 (en) * 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
PT2946765T (pt) 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US20170360929A1 (en) 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
WO2017019862A1 (en) * 2015-07-30 2017-02-02 Teva Pharmaceuticals Industries Ltd. Combination formulation of laquinimod and glatiramer acetate with amino acids
WO2017031151A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
EP3355990B1 (en) 2015-09-30 2019-06-12 Novaliq GmbH Semifluorinated compounds and their compositions
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
WO2017083525A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
ES2970186T3 (es) * 2015-11-25 2024-05-27 Immunogen Inc Formulaciones farmacéuticas y métodos de uso de las mismas
HUE050811T2 (hu) * 2015-12-07 2021-01-28 Merck Patent Gmbh Avelumab anti-PD-1 ellenanyagot tartalmazó vizes gyógyászati kiszerelés
JP6993699B2 (ja) 2016-01-11 2022-02-03 ウニヴェルズィテート・ツューリヒ ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
US20190284282A1 (en) * 2016-01-12 2019-09-19 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition
ES2983242T3 (es) 2016-01-13 2024-10-22 Genmab As Formulación para anticuerpo y conjugado de fármaco del mismo
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US20180043020A1 (en) * 2016-04-20 2018-02-15 Coherus Biosciences, Inc. Method of reducing immunogenicity of drug products
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US10507132B2 (en) 2016-06-23 2019-12-17 Novaliq Gmbh Topical administration method
HUP1600456A2 (en) 2016-07-19 2018-01-29 Richter Gedeon Nyrt Novel cell-based tnf-alpha binding assay
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
KR102413592B1 (ko) 2016-10-21 2022-06-27 암젠 인크 약학적 제형 및 그의 제조 방법
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
CA3049857A1 (en) 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
CA3044082A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2018184693A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
CN106918633B (zh) * 2017-04-24 2019-06-25 中国科学院苏州生物医学工程技术研究所 基于适体和金磁纳米颗粒的细胞因子TNF-α的检测方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR20200003107A (ko) 2017-05-02 2020-01-08 머크 샤프 앤드 돔 코포레이션 항-lag3 항체의 제제, 및 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
US11136138B2 (en) 2017-07-10 2021-10-05 Autel Robotics Co., Ltd. Aircraft control method and apparatus and aircraft
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
JP2020534366A (ja) * 2017-09-20 2020-11-26 アルヴォテック エイチエフ アダリムマブ用医薬製剤
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
CA3076567A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh Ophthalmic compositions
MX2017016884A (es) * 2017-12-19 2019-06-20 Probiomed S A De C V Formulacion farmaceutica estable de una proteina anti-tnfa.
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US12139533B2 (en) 2017-12-20 2024-11-12 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-CD200 antibodies
CN108414479A (zh) * 2018-01-19 2018-08-17 祝胜郎 一种免疫组合物在制备IgA肾病无创检测用试剂中的用途
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂
CN110302377B (zh) * 2018-02-11 2020-04-17 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂
SG11202007858VA (en) 2018-03-02 2020-09-29 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
KR102861021B1 (ko) 2018-05-07 2025-09-17 젠맵 에이/에스 항-pd-1 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CA3118144A1 (en) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
KR20210096559A (ko) 2018-11-27 2021-08-05 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항IL-23p19 항체 및 이의 용도
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
WO2021209017A1 (zh) * 2020-04-17 2021-10-21 苏州丁孚靶点生物技术有限公司 一种特异性结合cd137的制剂及其用途
CA3178853A1 (en) * 2020-05-13 2021-11-18 Wei Cao Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
IL299570A (en) * 2020-06-29 2023-02-01 Kodiscovery Llc Cellular energy inhibitor formulations for the treatment of pathogenic infections and associated methods
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
EP4329804A4 (en) * 2021-04-26 2025-03-19 TrueBinding, Inc. Anti-gal3 antibody formulations and methods of use thereof
AU2022348349A1 (en) * 2021-09-16 2024-05-02 Aprogen Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFα ANTIBODY
TW202328209A (zh) * 2021-11-10 2023-07-16 美商健生生物科技公司 包含雙特異性ｂｃｍａ／ｃｄ３抗體之穩定配方
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS605899B2 (ja) 1975-04-10 1985-02-14 中外製薬株式会社 免疫化学的定量法
US4396608A (en) 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
IE833023L (en) * 1983-01-28 1984-07-28 Joseph Patrick Mcauliffe System and process of identifying and updating tuning¹constants
EP0168506B2 (en) 1984-07-07 1998-01-07 Armour Pharma GmbH Process for preparing gamma globulin suitable for intravenous administration
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0230574A3 (en) 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
EP0417191B1 (en) 1988-05-27 1993-03-10 Centocor, Inc. Formulation for antibody reagents
AU4056689A (en) 1988-07-27 1990-02-19 Bmc Software, Inc. Improved data transmission optimizer
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
ES2096553T3 (es) 1988-12-19 1997-03-16 American Cyanamid Co Metodo para el tratamiento de choque endotoxico en un animal mamifero.
EP0465513A1 (en) 1989-03-27 1992-01-15 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
AU640400B2 (en) 1989-08-07 1993-08-26 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5998378A (en) 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
JPH0791318B2 (ja) 1989-09-21 1995-10-04 三井東圧化学株式会社 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
JPH06500323A (ja) 1990-08-27 1994-01-13 ペプチド　テクノロジィ　リミテッド ウイルス性感染の治療方法
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
US20060246073A1 (en) * 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DK0610201T4 (da) 1991-03-18 2008-02-04 Centocor Inc Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor
DE69130262T2 (de) 1991-03-29 1999-03-18 Immunex Corp., Seattle, Wash. Isolierte virale proteine als cytokinantagonisten
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU3244693A (en) 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
MX9301942A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Derivados de ciclohexan-ilideno novedosos.
DE69321909T2 (de) 1992-08-28 1999-04-01 Bayer Corp., Pittsburgh, Pa. Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
WO1994008609A1 (en) 1992-10-15 1994-04-28 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
DE4307508A1 (de) 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
FR2708467B1 (fr) 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
ZA955642B (en) * 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE234918T1 (de) 1995-08-04 2003-04-15 Lek Tovarna Farmacevtskih Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DE122004000003I2 (de) * 1996-02-09 2007-03-29 Abbott Biotech Ltd Humane Antikörper welche an humanen TNFalpha Binden
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0938334A4 (en) 1996-07-26 2004-12-15 Smithkline Beecham Corp IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
EP0973549A2 (en) 1997-04-07 2000-01-26 Cangene Corporation Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2635352C (en) * 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
PT911037E (pt) * 1997-10-23 2002-12-31 Mitsubishi Pharma Corp Preparacao de imunoglobulina armazenavel a temperatura ambiente para injeccao intravenosa
ES2179414T3 (es) 1997-11-22 2003-01-16 Roche Diagnostics Gmbh Procedimiento mejorado de estabilizacion de proteinas.
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
JP4685238B2 (ja) 1998-06-09 2011-05-18 ツエー・エス・エル・ベーリング・アクチエンゲゼルシヤフト 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
GB9819019D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6537549B2 (en) 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6419934B1 (en) 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6379666B1 (en) 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
WO2000056772A1 (en) 1999-03-25 2000-09-28 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
CA2371427A1 (en) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
WO2000067798A2 (en) 1999-05-05 2000-11-16 Elan Corporation Plc Enhanced delivery of nucleic acid-based drugs
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
CN101518653B (zh) 1999-06-25 2015-08-19 基因技术股份有限公司 使用抗ErbB抗体-类美坦素偶联物的治疗方法
KR100567292B1 (ko) 1999-12-14 2006-04-04 제넨테크, 인크. Ｌｆａ-1 또는 ｔｎｆ-알파 매개 질환의 치료용ｔｎｆ-알파 길항제 및 ｌｆａ-1 길항제
WO2001047554A1 (fr) * 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
AU750296B2 (en) 2000-06-23 2002-07-11 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
AU2001276737A1 (en) * 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
DK1314437T3 (da) * 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
SE0003045D0 (sv) * 2000-08-29 2000-08-29 Probi Ab New method
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
WO2002043750A2 (en) 2000-12-01 2002-06-06 Battelle Memorial Institute Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
KR100923514B1 (ko) 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
KR20020066778A (ko) 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
US6850177B2 (en) 2001-05-14 2005-02-01 Xyron Corporation Digital to analog convertor
WO2002096461A1 (en) * 2001-05-25 2002-12-05 Abbott Gmbh & Co. Kg Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
JP5052736B2 (ja) * 2001-05-30 2012-10-17 中外製薬株式会社 タンパク質製剤
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
PT1397155E (pt) * 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
GB0202633D0 (en) 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
JP3792698B2 (ja) * 2002-02-14 2006-07-05 中外製薬株式会社 抗体含有溶液製剤
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US20050276823A1 (en) 2002-07-12 2005-12-15 Cini John K Methods and compositions for preventing oxidative degradation of proteins
CA2800126A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
UY28126A1 (es) 2002-12-24 2004-06-30 Alcon Inc Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
DE602004003101T2 (de) 2003-04-25 2007-02-15 S.C. Johnson & Son, Inc., Racine Am rand eines toilettenbeckens angebrachte vorrichtung zur abgabe von zwei flüssigkeiten
DE602005016659D1 (de) 2004-03-18 2009-10-29 R Tech Ueno Ltd Wässrige zusammensetzung mit einem thiazol-derivat
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
WO2006125229A2 (en) * 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7919264B2 (en) * 2005-11-01 2011-04-05 Abbott Biotechnology Ltd. Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers
KR20140071452A (ko) * 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
EP2012586A4 (en) * 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
CN107243099A (zh) 2006-06-30 2017-10-13 艾伯维生物技术有限公司 自动注射装置
DE502006002128D1 (de) 2006-07-25 2009-01-02 Claus Herdeis Herstellung von antimikrobiellen Formulierungen unter Verwendung von 7-Oxa-2-thia 1,5-diazabicycloÄ3.3.1Ünonan-2,2-dion
CN101663390B (zh) * 2006-09-13 2013-10-23 Abbvie公司 使用非动物源水解产物的分批补料细胞培养方法
CN104072612A (zh) 2006-10-27 2014-10-01 艾伯维生物技术有限公司 结晶型抗-hTNFα抗体
EP2679995A1 (en) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
WO2008150490A2 (en) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
WO2008154543A2 (en) * 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CN101848733A (zh) * 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
CA2697163A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
US8969024B2 (en) 2007-08-28 2015-03-03 Abbvie Biotechnology Ltd Compositions and methods comprising binding proteins for adalimumab
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP3189831A1 (en) 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Protein formulations and methods of making same
CA2710333A1 (en) * 2008-01-03 2009-07-09 Abbott Biotechnology Ltd. Predicting long-term efficacy of a compound in the treatment of psoriasis
TWI478937B (zh) * 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
AU2009204863B2 (en) * 2008-01-15 2015-07-16 AbbVie Deutschland GmbH & Co. KG Powdered protein compositions and methods of making same
EP2271671A2 (en) 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
EP3912639A1 (en) 2012-03-07 2021-11-24 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab

Also Published As

Publication number Publication date
CN102078608A (zh) 2011-06-01
IL166809A (en) 2015-02-26
US8916157B2 (en) 2014-12-23
TWI331532B (en) 2010-10-11
US8911741B2 (en) 2014-12-16
US9327032B2 (en) 2016-05-03
KR20110036870A (ko) 2011-04-11
US20150344562A1 (en) 2015-12-03
US8940305B2 (en) 2015-01-27
US20140314781A1 (en) 2014-10-23
WO2004016286A2 (en) 2004-02-26
PL218834B1 (pl) 2015-01-30
US9272041B2 (en) 2016-03-01
PT1528933E (pt) 2012-07-23
AU2003267744C1 (en) 2015-09-17
CA2882931A1 (en) 2004-02-26
CL2010000603A1 (es) 2010-11-12
US20140322228A1 (en) 2014-10-30
US9732152B2 (en) 2017-08-15
US9114166B2 (en) 2015-08-25
US20150344563A1 (en) 2015-12-03
US9738714B2 (en) 2017-08-22
US20150093394A1 (en) 2015-04-02
PL218221B1 (pl) 2014-10-31
US20060153846A1 (en) 2006-07-13
EP2363144A1 (en) 2011-09-07
BR0313492A (pt) 2005-07-05
JP2014074034A (ja) 2014-04-24
MY163027A (en) 2017-07-31
KR101529583B1 (ko) 2015-06-18
CA2882907A1 (en) 2004-02-26
IL207028A0 (en) 2010-12-30
CY1118991T1 (el) 2018-01-10
US8802102B2 (en) 2014-08-12
NZ538030A (en) 2006-10-27
CA2872088A1 (en) 2004-02-26
JP5608619B2 (ja) 2014-10-15
US9272042B2 (en) 2016-03-01
CA2872091A1 (en) 2004-02-26
CA2882905A1 (en) 2004-02-26
CN102078608B (zh) 2016-04-13
IL207028A (en) 2015-11-30
PT2359856T (pt) 2017-06-23
KR20120130258A (ko) 2012-11-29
US20140086929A1 (en) 2014-03-27
US20140341925A1 (en) 2014-11-20
EP2359856A1 (en) 2011-08-24
PE20040994A1 (es) 2004-12-27
EP2361637A1 (en) 2011-08-31
US20140086931A1 (en) 2014-03-27
US20170145087A1 (en) 2017-05-25
PL406852A1 (pl) 2014-03-31
CA2882907C (en) 2015-07-28
US20170158759A1 (en) 2017-06-08
SI2359856T1 (sl) 2017-08-31
MXPA05001841A (es) 2005-09-30
CA2882934A1 (en) 2004-02-26
JP2006511457A (ja) 2006-04-06
JP2017165736A (ja) 2017-09-21
MY153718A (en) 2015-03-13
US9750808B2 (en) 2017-09-05
US20220241415A1 (en) 2022-08-04
EP1528933B1 (en) 2012-05-02
CN102049045A (zh) 2011-05-11
ES2387616T3 (es) 2012-09-27
CY1113353T1 (el) 2016-06-22
US20170151329A1 (en) 2017-06-01
EP2359856B1 (en) 2017-05-10
US9302011B2 (en) 2016-04-05
US20040033228A1 (en) 2004-02-19
US20150306224A1 (en) 2015-10-29
PL375272A1 (pl) 2005-11-28
US8802101B2 (en) 2014-08-12
US8216583B2 (en) 2012-07-10
US20210113694A1 (en) 2021-04-22
CA2882905C (en) 2015-07-28
KR20050067140A (ko) 2005-06-30
DK1528933T3 (da) 2012-07-23
US8795670B2 (en) 2014-08-05
WO2004016286A3 (en) 2004-07-22
KR20140092236A (ko) 2014-07-23
HK1074008A1 (en) 2005-10-28
AR077412A2 (es) 2011-08-24
CN1688339B (zh) 2012-05-09
US8802100B2 (en) 2014-08-12
US9289497B2 (en) 2016-03-22
CA2494756A1 (en) 2004-02-26
TW200500083A (en) 2005-01-01
US20150344560A1 (en) 2015-12-03
SI1528933T1 (sl) 2012-09-28
KR101367743B1 (ko) 2014-02-27
CA2854798A1 (en) 2004-02-26
US20170056498A1 (en) 2017-03-02
UY27940A1 (es) 2004-03-31
CA2872089A1 (en) 2004-02-26
US20140127222A1 (en) 2014-05-08
EP1528933A2 (en) 2005-05-11
JP4925582B2 (ja) 2012-04-25
CN101721702B (zh) 2014-12-10
JP2015199741A (ja) 2015-11-12
US20150344561A1 (en) 2015-12-03
PL212934B1 (pl) 2012-12-31
US20120282270A1 (en) 2012-11-08
AR040881A1 (es) 2005-04-20
CA2882931C (en) 2016-08-09
US8916158B2 (en) 2014-12-23
US20150343065A1 (en) 2015-12-03
US20140086930A1 (en) 2014-03-27
ATE555809T1 (de) 2012-05-15
CN101721702A (zh) 2010-06-09
US20190054171A1 (en) 2019-02-21
CN1688339A (zh) 2005-10-26
CA2882934C (en) 2015-07-28
CN102049045B (zh) 2016-05-25
DK2359856T3 (en) 2017-07-17
EP2363145A1 (en) 2011-09-07
US8932591B2 (en) 2015-01-13
US20180339046A1 (en) 2018-11-29
US9950066B2 (en) 2018-04-24
ZA200501032B (en) 2006-02-22
US9220781B2 (en) 2015-12-29
MY162068A (en) 2017-05-31
US9295725B2 (en) 2016-03-29
ES2636692T3 (es) 2017-10-06
US20140341924A1 (en) 2014-11-20
IL166809A0 (en) 2006-01-15
CA2494756C (en) 2014-07-22
JP2012046527A (ja) 2012-03-08
CA2872089C (en) 2015-07-14
US20160030578A1 (en) 2016-02-04
KR101273568B1 (ko) 2013-06-11
AU2003267744A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
PL398596A1 (pl) Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α
AU2003286567A8 (en) Methods for the treatment of skin disorders
TWI367102B (en) Therapeutic human anti-il-1r1 monoclonal antibody
IL174918A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL174185A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP1482972A4 (en) TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
AU2003216592A8 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
PL374118A1 (pl) Receptory interleukiny-1 w leczeniu chorób
EP1560593A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
EP1578373A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
IL168065A0 (en) Herbal medicine containing cyclodextrins for the treatment of ear disorders
EP1562587A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM
IL172511A0 (en) Specific human antibodies
AU2003287016A8 (en) Human sarcoma-associated antigens
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
IL164951A0 (en) The treatment of pain with lfendropil
WO2004096848A8 (en) Novel composition and methods for the treatment of immune disorders
GB0201025D0 (en) The treatment of degenerative diseases
AU2003215609A1 (en) Use of biogenic estriol sulfamate prodrugs for the treatment of autoimmune diseases
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
AU2003297912A1 (en) Methods for screening compounds for use in the treatment of disease
GB0325957D0 (en) The treatment of pain